Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytovene I.V. Shortage Will Be Resolved by Second Quarter, Roche Says

Executive Summary

Roche expects to resolve a shortage of Cytovene I.V. by the second quarter

You may also be interested in...



Roche Cytovene I.V. shortage lengthens

Roche expects "intermittent complete out-of-stock situations" for Cytovene I.V. to continue until the middle of the second quarter. "Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply" ganciclovir, a Feb. 6 "Dear Doctor" letter says. Roche had expected to resolve the shortage of the CMV retinitis product by the second quarter (1"The Pink Sheet" Jan. 14, p. 19)....

Roche Cytovene I.V. shortage lengthens

Roche expects "intermittent complete out-of-stock situations" for Cytovene I.V. to continue until the middle of the second quarter. "Despite the implementation of a system to manage the available stock, demand exceeds our ability to supply" ganciclovir, a Feb. 6 "Dear Doctor" letter says. Roche had expected to resolve the shortage of the CMV retinitis product by the second quarter (1"The Pink Sheet" Jan. 14, p. 19)....

Roche Valcyte Expected To Erode Ganciclovir Scripts After Spring Launch

Roche anticipates that Valcyte (valganciclovir) will begin to erode oral Cytovene (ganciclovir) prescriptions for the treatment of cytomegalovirus retinitis in AIDS patients following spring launch.

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel